It is worth noting that these assays were predominantly commercial, with the Myriad MyChoice® CDx kit being the most prevalent at 46%, followed closely by Myriad BRACAnalysis® CDx at 40%, FoundationOne® CDx at 17%, and the BROCA Cancer Risk Panel at 6% of the studies that looked at BRCA1/2. This evidence concerns the gene BRCA1 and cancer.